Article · Research

Retatrutide weight loss: New trial data and South African risks

New trial data presented on 29 September 2026 shows that retatrutide, an investigational triple agonist, led to an average of 20.8% weight loss over 80 weeks in participants with obesity and type 2 diabetes. While these results are significant, the drug is not registered in South Africa, and regulators warn that unregulated versions sold online or on the black market pose serious health risks.

New trial results for retatrutide

The results of the TRIUMPH-2 study were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes and simultaneously published in The Lancet on 29 September 2026. The study involved participants with a baseline Body Mass Index (BMI) of 27 or higher and type 2 diabetes mellitus. According to The Pharmaceutical Journal, participants who took retatrutide at a dose of 12 mg experienced an average of 20.8% weight loss over 80 weeks.

The same publication reported that nearly one-quarter of participants with a baseline BMI of 35 or higher who took the 12 mg dose lost an average of 28 kg. Furthermore, more than half of the participants no longer met the BMI criteria for obesity by the end of the trial. For context, previous studies in people without diabetes showed an average weight loss of 28.3% over the same period on the 12 mg dose.

Study Population Dose Average Weight Loss Duration
Obesity and Type 2 Diabetes 12 mg 20.8% 80 weeks
Obesity (without diabetes) 12 mg 28.3% 80 weeks

Regulatory risks in South Africa

Despite promising international data, retatrutide is an investigational compound and is not registered for use in South Africa. Vincent Tlala, registrar and CEO of the South African Pharmacy Council, warned on 29 September 2026 that unregulated peptides sold on the black market could pose serious health risks. He explained that many peptides are classified as Schedule 4 medicines and may only be manufactured, prescribed, sold or distributed by authorised providers registered with the South African Health Products Regulatory Authority (SAHPRA).

Tlala stated that such products can only be obtained through a prescription from a medical doctor and subsequently from a pharmacy. He cautioned against obtaining these substances from any other source. The Mail & Guardian reported on 22 October 2026 that South African regulators are struggling to keep up with black market sellers of weight-loss drugs, noting that illegal and experimental drugs are still being sold openly while new rules to crack down on the trade are months away.

Consumer caution

News24 reported on 24 October 2026 that some South Africans are using illicit weight-loss drugs, describing the practice as potentially dangerous. The article highlighted the risk of using products that have not been cleared for use. Given that retatrutide is still in clinical trials globally, consumers in South Africa cannot legally purchase it through standard pharmacy channels. Health experts advise caution regarding unproven claims and unregulated products available online or through informal networks.

See also: Is retatrutide legal in South Africa?

Frequently asked questions

What is retatrutide and how effective is it for weight loss?

Retatrutide is an investigational triple agonist drug. Trial data presented on 29 September 2026 showed it led to an average of 20.8% weight loss over 80 weeks in participants with obesity and type 2 diabetes taking a 12 mg dose.

Is retatrutide legally available in South Africa?

No, retatrutide is still an investigational compound and is not registered for use in South Africa. Consumers cannot legally purchase it through standard pharmacy channels.

What do South African regulators say about online or black market retatrutide?

Vincent Tlala, registrar and CEO of the South African Pharmacy Council, warned that unregulated peptides sold on the black market could pose serious health risks. Regulators are currently struggling to keep up with illicit sellers as new rules to crack down on the trade remain months away.

How can Schedule 4 medicines like peptides be legally obtained in South Africa?

Many peptides are classified as Schedule 4 medicines that can only be manufactured, prescribed, sold, or distributed by authorised providers. They must be obtained through a prescription from a medical doctor and subsequently from a pharmacy.

What specific trial results were published for patients with type 2 diabetes?

The TRIUMPH-2 study results were published in The Lancet on 29 September 2026. Participants with obesity and type 2 diabetes who took the 12 mg dose experienced an average weight loss of 20.8% over 80 weeks.

What warnings have health experts issued to South African consumers?

Health experts advise caution regarding unproven claims and unregulated products available online or through informal networks. Some South Africans are using illicit weight-loss drugs, a practice described by reports as potentially dangerous.

Sources

  1. The Pharmaceutical Journal, "Triple agonist drug retatrutide shows 21% weight loss in patients with diabetes", 2026-10-01, https://pharmaceutical-journal.com/article/news/triple-agonist-drug-retatrutide-shows-21-weight-loss-in-patients-with-diabetes
  2. EWN, "Warning over black market peptides as popularity grows", 2026-09-29, https://www.ewn.co.za/2026/09/30/warning-over-black-market-peptides-as-popularity-grows
  3. Mail & Guardian, "Black market weight-loss drug sellers are moving fast. SA’s regulators are struggling to keep up", 2026-10-22, https://mg.co.za/news/health/2026-10-22-black-market-weight-loss-drug-sellers-are-moving-fast-sa-s-regulators-are-struggling-to-keep-up
  4. News24, "A Reta revolution or Russian roulette? The illicit weight-loss drug South Africans are injecting", 2026-10-24, https://www.news24.com/southafrica/news/a-reta-revolution-or-russian-roulette-the-illicit-weight-loss-drug-south-africans-are-injecting-20261024-0812